An antibody-drug conjugate targeting trophoblast cell surface antigen 2:datopotamab deruxtecan
Trophoblast cell surface antigen 2(TROP2)is a tumor-associated calcium signal transducer that is widely expressed in the vast majority of non-small-cell lung cancer(NSCLC).Datopotamab deruxtecan(resarch code:DS-1062a)is a novel antibody-drug conjugate(ADC)targeting TROP2.Research indicates that it can delay disease progression or death,showing good anti-tumor activity and an acceptable safety profile.It is currently in phase Ⅲ clinical trials.This article provides an overview of the basic information,mechanism of action,preclinical studies,and clinical trials of datopotamab deruxtecan.
datopotamab deruxtecantrophoblast cell surface antigen 2antibody-drug conjugatenon-small-cell lung cancer
NETL
NSTL
万方数据
